Septerna, Inc. (SEPN) company profile
Close on Nov 17, 2026Market cap $1.87BP/E –Yield –
About Septerna
Pharmaceutical Preparations, SIC 2834
Septerna, Inc. is a clinical-stage biotechnology company that discovers and develops oral small molecule drugs targeting G protein-coupled receptors. The company utilizes a proprietary platform to isolate, purify, and reconstitute receptor proteins outside cells to guide structure-based drug design and optimization. Its development pipeline includes experimental product candidates such as SEP-479 and SEP-631, which focus on endocrinology, immunology, inflammation, and metabolic conditions. Septerna also partners with pharmaceutical companies, including Novo Nordisk, to develop oral therapies for disorders such as obesity and type 2 diabetes. Its programs aim to serve patient populations affected by these diseases.
The company operates in the United States, maintaining leased office, research, and laboratory facilities. Its principal executive offices are located in South San Francisco, California.
Summary of the business section of Septerna's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Septerna, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 250 East Grand Avenue, Suite 65 94080
- Phone
- (650) 338-3533
- Website
- septerna.com
- Employees
- 130, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- SEPN
- Exchange
- Nasdaq
- IPO date
- Oct 25, 2024
- Shares outstanding
- 47M, Aug 5, 2026
- Public float
- $363.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1984086
- CUSIP
- 81734D104
- ISIN
- US81734D1046
- FIGI
- BBG014WY1V28
- Share class FIGI
- BBG014WY1VC7
- EIN
- 84-3891440
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jeffrey Finer | Chief Executive Officer, Director | 833,909 |
| Elizabeth Bhatt | President and COO | 174,209 |
| Rajiv Patni | Chief Medical Officer | – |
| Daniel D. Long | SVP, Drug Discovery | 96,412 |
| Samira Shaikhly | Chief People Officer | 793 |
| Uwe Klein | SVP, Biological Sciences | 119,912 |
| Jae B. Kim | Chief Medical Officer | – |
| Mark Andrew Wilson | Chief Legal Officer | – |
| Gil M. Labrucherie | Chief Financial Officer | 40,000 |
| Alan Ezekowitz | Director | 35,600 |
| Capital Healthcare Fund LP RA | Director | – |
| Peter Kolchinsky | Director | – |
| RA Capital Nexus Fund III, L.P. | Director | – |
| Rajeev M. Shah | Director | 725,443 |
| Ra Capital Management, L.P. | Director | – |
| Shalini Sharp | Director | – |
| Keith Michael Gottesdiener | Director | – |
| Bernard Coulie | Director | – |
| Jeffrey K. Tong | Director | – |
| Abraham Bassan | Director | – |
| Jake Simson | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Jeffrey Finer, M.D., Ph.D Chief Executive Officer | $635.00K | $401.64K | $1.89M | $5.00K | $2.93M | -38% |
| Liz Bhatt, M.S., M.B.A President and Chief Operating Officer | $500.00K | $230.00K | $855.77K | $5.00K | $1.59M | -2% |
| Gil M. Labrucherie, CFA, J.D. Chief Financial Officer (4) | $479.49K | $223.10K | $2.54M | $2.43K | $3.24M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 25, 2024
- Offer price
- $18.00
- Securities offered
- 16,000,000
- Gross proceeds
- $288.00M
- Exchange
- Nasdaq
- First trading day
- Oct 25, 2024
- First-day close
- $21.40+18.9%
- Lock-up ends (est.)
- Apr 23, 2025
“The initial public offering price per share is $18.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 130 full-time employees, 67 of whom have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 25, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 22, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?